文献速递呼吸衰竭与机械通气

经鼻高流量氧疗与常规氧疗治疗急性低氧性呼吸衰竭的系统评价与荟萃分析

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis.
PubMed 文献 · Intensive Care Med · 2019-03-19
一句话结论在急性低氧性呼吸衰竭患者中,经鼻高流量氧疗可能减少气管插管需求,但不影响死亡率(RR 0.94,95%CI 0.67-1.31)。

该系统评价与荟萃分析纳入9项随机对照试验(n=2093)比较经鼻高流量氧疗(HFNC)与常规氧疗在急性低氧性呼吸衰竭患者中的安全性和有效性。结果显示HFNC组死亡率无差异(RR 0.94,95%CI 0.67-1.31,中等确定性),但插管风险降低(RR 0.85,95%CI 0.74-0.99)和氧疗升级风险降低(RR 0.71,95%CI 0.51-0.98),两者确定性低。HFNC对ICU住院时间、医院住院时间、患者舒适度和呼吸困难无显著影响。结论认为HFNC可能减少气管插管需求而不影响死亡率。

要点

  • 在急性低氧性呼吸衰竭患者中,HFNC与常规氧疗相比死亡率无差异(RR 0.94,95%CI 0.67-1.31,中等确定性)。
  • HFNC组需要插管的风险降低(RR 0.85,95%CI 0.74-0.99),但证据确定性低。
  • HFNC组氧疗升级风险降低(定义为对照组交叉至HFNC,或任一组开始无创通气或有创机械通气)(RR 0.71,95%CI 0.51-0.98),证据确定性低。
  • HFNC对ICU住院时间(MD增加1.38天,95%CI减少0.90天至增加3.66天,低确定性)和医院住院时间(MD减少0.85天,95%CI减少2.07天至增加0.37天,中等确定性)无显著影响。
  • HFNC对患者报告的舒适度(SMD降低0.12,95%CI降低0.61至升高0.37,极低确定性)和呼吸困难(SMD降低0.16,95%CI降低1.10至升高1.42,低确定性)无显著影响。

适用人群与场景

  • 急性低氧性呼吸衰竭患者(纳入随机对照试验比较HFNC与常规氧疗)。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入9项随机对照试验(n=2093例患者)。
  • 主要结果:HFNC组与常规氧疗组死亡率无差异(RR 0.94,95%CI 0.67-1.31,中等确定性)。
  • 插管风险:HFNC组降低(RR 0.85,95%CI 0.74-0.99),证据确定性低(因不精确和偏倚风险问题)。
  • 氧疗升级风险:HFNC组降低(RR 0.71,95%CI 0.51-0.98),证据确定性低(因不精确和偏倚风险问题)。
  • ICU住院时间:HFNC组平均增加1.38天(95%CI减少0.90天至增加3.66天,低确定性)。
  • 医院住院时间:HFNC组平均减少0.85天(95%CI减少2.07天至增加0.37天,中等确定性)。
  • 患者报告舒适度:SMD降低0.12(95%CI降低0.61至升高0.37,极低确定性)。
  • 患者报告呼吸困难:SMD降低0.16(95%CI降低1.10至升高1.42,低确定性)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验。
  • 证据确定性评估采用GRADE方法:死亡率中等确定性;插管和氧疗升级低确定性;ICU住院时间低确定性;医院住院时间中等确定性;舒适度极低确定性;呼吸困难低确定性。
  • 偏倚风险使用Cochrane工具评估。
  • 局限性:插管和氧疗升级结局的确定性低,归因于不精确和偏倚风险问题;治疗并发症在各研究中间报告不一,但HFNC使用相关伤害较少。

对床旁实践的改变

  • 在急性低氧性呼吸衰竭患者中,HFNC可能减少气管插管需求而不影响死亡率(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This systematic review and meta-analysis summarizes the safety and efficacy of high flow nasal cannula (HFNC) in patients with acute hypoxemic respiratory failure.

METHODS: We performed a comprehensive search of MEDLINE, EMBASE, and Web of Science. We identified randomized controlled trials that compared HFNC to conventional oxygen therapy. We pooled data and report summary estimates of effect using relative risk for dichotomous outcomes and mean difference or standardized mean difference for continuous outcomes, with 95% confidence intervals. We assessed risk of bias of included studies using the Cochrane tool and certainty in pooled effect estimates using GRADE methods.

RESULTS: We included 9 RCTs (n = 2093 patients). We found no difference in mortality in patients treated with HFNC (relative risk [RR] 0.94, 95% confidence interval [CI] 0.67-1.31, moderate certainty) compared to conventional oxygen therapy. We found a decreased risk of requiring intubation (RR 0.85, 95% CI 0.74-0.99) or escalation of oxygen therapy (defined as crossover to HFNC in the control group, or initiation of non-invasive ventilation or invasive mechanical ventilation in either group) favouring HFNC-treated patients (RR 0.71, 95% CI 0.51-0.98), although certainty in both outcomes was low due to imprecision and issues related to risk of bias. HFNC had no effect on intensive care unit length of stay (mean difference [MD] 1.38 days more, 95% CI 0.90 days fewer to 3.66 days more, low certainty), hospital length of stay (MD 0.85 days fewer, 95% CI 2.07 days fewer to 0.37 days more, moderate certainty), patient reported comfort (SMD 0.12 lower, 95% CI 0.61 lower to 0.37 higher, very low certainty) or patient reported dyspnea (standardized mean difference [SMD] 0.16 lower, 95% CI 1.10 lower to 1.42 higher, low certainty). Complications of treatment were variably reported amongst included studies, but little harm was associated with HFNC use.

CONCLUSION: In patients with acute hypoxemic respiratory failure, HFNC may decrease the need for tracheal intubation without impacting mortality.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rochwerg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019. PMID: 30888444. doi:10.1007/s00134-019-05590-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。